Big Cypress Acquisition today announced it filed a confidential draft S-4 with the SEC relating to its proposed business combination with SAB Biotherapeutics.
If the deal is approved, SAB plans to list on the Nasdaq following the closing of the transaction. The proposed transaction implies an enterprise value for SAB, on a post-merger basis, of approximately $325 million and is expected to provide the combined company with approximately $118 million of pro forma cash (assuming no redemptions from Big Cypress’ trust account).
SAB is a clinical-stage biopharmaceutical company that is developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. Read more.